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20 Abstract
21 Objectives: Rapid rate-of-kill (RoK) is a key parameter in the target candidate profile 1 (TCP1) for the 
22 next-generation antimalarial drugs for uncomplicated malaria, termed Single Encounter Radical Cure 
23 and Prophylaxis (SERCaP). TCP1 aims to rapidly eliminate the initial parasite burden, ideally as fast as 
24 artesunate, but minimally as fast as chloroquine. Here we explore whether the relative RoK of the 
25 Medicine for Malaria Venture (MMV) Malaria Box compounds are linked to their mode of action 
26 (MoA) and identify scaffolds of medicinal chemistry interest. 
27 Methods: We used a Bioluminescence Relative RoK (BRRoK) assay over 6 and 48h, with exposure to 
28 equipotent-IC50 concentrations, to compare the cytocidal effects of Malaria Box compounds to 
29 benchmark antimalarials.
30 Results: BRRoK assay data demonstrate the following relative RoK from fast to slow: inhibitors of 
31 PfATP4 > parasite hemoglobin catabolism > DHFR-TS > DHODH > bc1 complex. Core scaffold 
32 clustering analyses reveal intrinsic rapid cytocidal action for diamino-glycerols and 2-
33 (aminomethyl)phenol, but slow action for 2-phenylbenzimidazoles, 8-hydroxyquinolines, and 
34 triazolopyrimidines. 
35 Conclusion: This study provides proof of principle that a compounds RoK is related to its MoA, and 
36 targets intrinsic RoK is also modified by factors affecting a drugs access to it. Our findings highlight 
37 that as we use medicinal chemistry to improve potency, we can also improve the RoK for some 
38 scaffolds. Our BRRoK assay provides the necessary throughput for drug discovery and a critical 
39 decision-making tool to support development campaigns. Finally, two scaffolds, diamino-glycerols, 
40 and 2-phenoxybenzylamine, exhibit fast cytocidal action, inviting medicinal chemistry improvements 
41 towards TCP1 candidates.
42
43
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44 Introduction
45 Resistance by P. falciparum to front-line therapeutics necessitates new drugs with novel 
46 MoA to circumvent parasite resistance mechanisms.1,2 This need was initially met by the 
47 identification of 20,000 hits with sub-micromolar potency against P. falciparum intraerythrocytic 
48 stages from an extensive screening campaign of around four million compounds from the libraries of 
49 St. Jude Children's Research Hospital, TN, USA, Novartis and GSK. 26 Triaging these hits to establish 
50 development priorities requires additional pharmacodynamic information, key amongst which is 
51 their rate-of-kill (RoK).7 Rapid RoK is specifically identified by MMV as a key requirement within a 
52 future SERCaP to treat malaria.1,8 The target candidate profile TCP1 requires an immediate effect to 
53 rapidly eliminate parasites, minimally as fast as chloroquine and ideally as fast as artesunate. If 
54 resistance renders artemisinin ineffective, TCP1 candidates will ideally replace it.1,8
55 Antimalarial RoK is currently determined in vivo with mouse models or phase IIa clinical 
56 trials.9 It is defined by (i) the parasite reduction ratio (PRR), the fold-reduction from starting 
57 parasitaemia after 48 hours (h, one erythrocyte-stage cycle) of treatment and (ii) parasite clearance 
58 time (PCT), time until parasites are no longer detectable in peripheral blood films9. The only in vitro 
59 RoK assay that provides the PRR and PCT parameters is the recrudescence assay at GSK Tres 
60 Cantos,10 representing the gold-standard for RoK determination in vitro. However, its challenging 
61 technical aspects, such as requirements for parasite recrudescence over 21-28-days, limit 
62 applicability to small-scale lead validation.7,1113 To address this assay bottleneck, we reported a 
63 microplate-based BRRoK assay that discriminates between minimum essential and ideal TCP1 
64 candidates within 6h (BRRoK6h), 10 and published RoK data for 370 open-access Medicine for Malaria 
65 Ventures Malaria Box compounds relative to a panel of known antimalarial benchmarks. 2,7 In this 
66 study, we extend this study of RoK for the Malaria Box compounds to demonstrate the following 
67 proof-of-principles. First, to show that compounds with similar BRRoK have similar MoA, we 
68 compared BRRoK6h from Malaria Box compounds to their predicted MoA. Five clusters emerged, 
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69 with each representing distinct relative RoK correlating with different MoA. Second, to demonstrate 
70 that Malaria Box compounds with related scaffolds have similar rates of antimalarial killing, BRRoK6h 
71 were compared based on compounds core scaffold with five clusters emerging that we then 
72 correlated with what we know about potential MoA. Third, we had previously identified 178 Malaria 
73 Box compounds that showed little cytocidal activity within 6h.10 Thus, we extended the assay over 
74 48h (BBRoK48h) to ensure completion of one intraerythrocytic cycle. Most compounds without 
75 activity in the BRRoK6h showed activity in the BRRoK48h, providing links to their MoA. Our data 
76 demonstrates that a revised BRRoK assay at two timepoints, 6 and 48h, provides a critical decision-
77 making tool for antimalarial drug discovery and development campaigns. 
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79 Methods 
80 The transgenic Dd2 P. falciparum clone (Dd2luc)14,15 were cultured as described previously.7 
81 The antimalarial drugs and the Malaria Box compounds were prepared as shown in Table S1. Malaria 
82 Box IC50 were measured in Dd2luc and deposited in the ChEMBL  Neglected Tropical Disease Open 
83 Access repository (ChEMBL3392923, see Van-Voorhis et al.,16).
84 The BRRoK48h assay was carried out as described previously7. Briefly, compounds were 
85 serially diluted (9×IC50, 3xIC50, 1xIC50 and 18KL
(50 concentrations from a determination of IC50 at 
86 48h) in 96-multiwell plates, trophozoite-stage (2026 h post-infection) cultures of Dd2luc were added 
87 and mixed by pipetting to give a final 200 M* volume in each well with 3-fold IC50 dilution series of 
88 drugs, 1% parasitaemia and 2% haematocrit. To estimate the BRRoK48h, the plates were incubated 
89 continuously in the presence of the compounds for 48h prior to assay at 37°C. As described 
90 previously, 7,17 40PM* of P. falciparum culture were transferred to a white 96-multiwell plate (Greiner, 
91 UK) and lysed with 10PM* of passive lysis buffer (Promega, UK). An equal volume, 50PM* of the 
92 supplied luminogenic substrate was mixed with the lysed parasites and the bioluminescence was 
93 measured for 2Ps in a Glomax-Multi Detection System (Promega, UK). Experiments were carried out 
94 as technical triplicates on the same plate, with three independent biological repeats of each plate 
95 performed. Controls in each biological replicate consisted of trophozoite-stage culture with no drug 
96 added (100%) or uninfected erythrocytes (0%). The mean and standard deviation (SD) of 
97 bioluminescence data from three independent biological repeats were expressed as a proportion of 
98 the untreated control (100%) and calculated as follows: 11LK QM<=LRLM <R=SM <:=LRLM <R=T where M<= 
99 M (+) and M <R= represent the means for the sample in question and 100% and 0% controls, 
100 respectively. The ZU score of the BRRoK48h assay was calculated as follows: ZULVLLRL 
101 [(3(+)L:L<R=)/(+)LRL<R=], where (+)and (+) are the mean and SD of the no-drug (untreated) positive 
102 control, respectively, and <R= and <R= are the mean and SD from uninfected erythrocytes (negative 
103 control), respectively.18 The signal/background (S/B) ratio was calculated as follows: [(+)<R=]/<R=. 
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104 As previously described,7 a principle components analysis (PCA) was performed on the BRRoK assay 
105 data for the MMV Malaria Box compounds (48h assays using a 9×IC50, 3xIC50, 1xIC50 and 
106 18KL
(50 series) using the KNIME analytics platform, to reduce the dimensionality of these data 
107 sets19, allowing the concentration-rate relationship to be captured in one parameter. The first 
108 principle component (PC1) accounted for 78% of the total variance of the data (see supplementary 
109 materials). A zero-meaned PC1 value is used to provide a description of the RoK relative to known 
110 antimalarial benchmark controls (see Table S1).7 
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112 Results 
113 The BRRoK6h for the Malaria Box identifies compound clusters linked by common modes of 
114 antimalarial action 
115 That antiplasmodial in vitro RoK correlates with MoA has been established for a small 
116 number of antimalarial drugs, predominantly within classes that have been or are currently used.10 
117 We have previously described a determination of the rates of initial cytocidal kill (over 6h) using the 
118 Bioluminescence Relative Rate of Kill (BRRoK) assay for 370 compounds from the Malaria Box open-
119 access drug discovery resource relative to a range of benchmark antimalarials for which both in vitro 
120 and in vivo rates of kill data were available.7 This determination used a P. falciparum strain 
121 genetically modified to express a bioluminescent luciferase reporter protein, with cytocidal action 
122 determined by loss of bioluminescent signal following exposure to increasing concentrations of test 
123 compound. Analysis of the normalised concentration-dependant bioluminescent signals by principle 
124 components analysis provides for a rank of initial cytocidal action that enables rate of kill relative to 
125 known controls to be described. Termed PC1, for first principle component, these are presented as 
126 zero-meaned data where low values such as -97.4 relate to the extremely rapid acting 
127 dihydroartemisinin and higher values, such as 55.4, for the slow-acting atovaquone.7 
128 With BRRoK6h data for 370 Malaria Box compounds, we correlated these with MoA data 
129 made available as part of this open source drug discovery project (Figure 1).2034  PC1 were plotted 
130 against their IC50 (ChEMBL3392923, see Van-Voorhis et al.,16) and mapped against benchmark 
131 antimalarials. Compounds with RoK X dihydroartemisinin (DHA, PC1= -97.4) and X chloroquine (CQ, 
132 PC1 = -73.7, log PRR= 4.5, 99% PCT= 32h) meet the TCP1 ideal and minimum essential criteria, 
133 respectively. Generally, compounds with RoK X CQ are considered fasting acting, those with a RoK X 
134 Quinine (QN, PC1 = -52), Mefloquine (MQ, -(LVLR8 log -''LVL8	 and 99.9% -(LVLPh) or 
135 Piperaquine (PQ, PC1 = -37, log PRR = 4.6, 99% PCT = 33h) are considered moderate acting, and 
136 those with RoK X Atovaquone (ATQ, PC1L8 log -''LVL8, and 99.9% -(LVL,1Ph) are slow-acting 
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137 (Figure 1, S1 Table). Thus, compounds with an initial rapid RoK and nM potency, like artemisinins, 
138 occupy the bottom-left quadrant those such as atovaquone, whilst potent, being slow-acting 
139 occupies the upper left-hand quadrant (Figure 1). 
140 MoA data was sourced from specific activity assays (e.g. in vitro enzyme inhibition assays) to 
141 comparative metabalomic profiling, and as such the MoA association for the Malaria Box are often 
142 tentative. We hypothesized that compounds with a shared MoA would exhibit similar BRRoK6h data. 
143 Five MoA including compounds targeting (i) PfATP4, a Na+-ATPase in the parasites plasma 
144 membrane, ii) bifunctional Plasmodium enzyme dihydrofolate reductase-thymidylate synthase 
145 (DHFR-TS), (iii) dihydroorotate dehydrogenase (DHODH), (iv) the bc1 complex of the mitochondrial 
146 electron transport chain and (v) parasite hemoglobin catabolism (Figure 1A-E) were clustered. These 
147 MoA were selected because in vitro PRR data are available for > 10 compounds (Table S2) in each 
148 class.16,20,21,27,28,35 RoK were identified from fast to slow: PfATP4 > parasite hemoglobin catabolism > 
149 DHFR-TS > DHODH > bc1 complex. Using one-way ANOVA with a post-hoc Tukey test 7,16,20,29,30, we 
150 found that compounds targeting PfATP4 exhibit the fastest RoK and are significantly faster than 
151 other clusters (Figure 1F). Compounds targeting parasite hemoglobin catabolism are significantly 
152 faster than those targeting DHFR-TS, DHODH and bc1 complex, and compounds targeting DHFR-TS 
153 are faster than DHODH and bc1 complex inhibitors (all p < 0.01), while other pairwise comparisons 
154 are not significant. 
155 BRRoK6h highlights rapid cytocidal activity for diamino-glycerols and 2-(aminomethyl)phenol 
156 scaffolds in the Malaria Box
157 The Malaria Box compounds were selected to be structurally diverse.2 We wished to 
158 determine whether substructure analysis of these novel Malaria Box compounds reveals novel core 
159 scaffolds with shared RoK activity, and thus potentially with new MoA. BRRoK6h data was overlaid 
160 with five distinct scaffolds; diamino-glycerols, 2-(aminomethyl)phenol, 2-phenylbenzimidazole, 8-
161 hydroxyquinolines, and triazolopyrimidine (Figure 2). Table S3 shows full structures and the core 
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162 scaffold substructures, with > 5 compounds for each scaffold annotated. We found a fast BRRoK for 
163 diamino-glycerols and 2-(aminomethyl)phenols, and slow BRRoK for 2-phenylbenzimidazoles, 8-
164 hydroxyquinolines and triazolopyrimidines (Figure 2A-E). The five core scaffolds identified BRRoK 
165 ranking from fast to slow: diamino-glycerols > 2-(aminomethyl)phenol > 2-phenylbenzimidazole > 8-
166 hydroxyquinolines > triazolopyrimidine. The diamino-glycerol scaffold exhibited the fastest cytocidal 
167 action among the group (p < 0.01 for all, except 2-(aminomethyl)phenol where p > 0.05 by ANOVA 
168 (Figure 2F). Similarly, compounds in the 2-(aminomethyl)phenol scaffold exhibited significantly faster 
169 action (p < 0.01) than the 2-phenylbenzimidazole, 8-hydroxyquinolines and triazolopyrimidine 
170 scaffolds (Figure 2F).
171 BRRoK48h confirms slow cytocidal action for a subset of compounds in the Malaria Box 
172 The BRRoK6h assay identified fast-acting Malaria Box compounds as TCP1 candidates, 
173 including the fastest-acting PfATP4 inhibitor spiroindolone MMV396749 (Table S2). However, almost 
174 half of the Malaria Box showed little cytocidal activity against intraerythrocytic trophozoites over 6h. 
175 We predicted that these compounds might have a lag phase in their cytocidal action, such as shown 
176 by the antimalarial atovaquone with a 48h lag in cytocidal action.10 We therefore employed a revised 
177 BRRoK assay over 48h (BRRoK48h) to ensure completion of one full intraerythrocytic cycle. For 
178 validation, we selected different benchmark antimalarials, which covered multiple MoA.7 Dd2luc 
179 parasites were exposed to a 3-fold serial dilution (918LKL
(50) for 48h, the resulting 
180 bioluminescence signal normalized to an untreated control, and the normalized bioluminescent 
181 signal plotted against drug concentration (Figure S1). We found the identical relative ranking order 
182 of benchmark antimalarial drugs (i.e. %LDL@LDL;
183 %@LDL!@= to  BRRoK6h,7 which is identical to both the in vivo and in 
184 vitro RoK.3133,35 
185 We had sufficient material available for 178 slow-acting Malaria Box compounds. Along with the 
186 benchmark antimalarial drugs ATQ, CQ, DHA, MQ, PPQ, pyronaridine (PYN) and QN, we subjected 
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187 them to a BRRoK48h assay (Table S4; Figures S2, S3). 95% confidence intervals for the ZU score (0.85-
188 0.95), maximum coefficient of variation (0.9%-2.84%), and signal/background ratio (2580-5001) 
189 indicate a robust and sensitive microplate-based assay of the BRRoK48h data. Using mean ± SD for 
190 each IC50-fold BRRoK48h normalized bioluminescent signal, a PCA was carried out for concentration-
191 dependent effects (Figure S4; Tables S5-S6). PC1 accounts for 78% of the variance at 48h, with most 
192 contributions provided by the 3X IC50 data. 
193 We next plotted BRRoK6h and BRRoK48h PC1 against IC50 data (Figure 3, Table S7). Figure 3A 
194 highlights these compounds slow action over 6 h, with compounds clustering adjacent to the slow 
195 acting atovaquone. Plotting BRRoK48h data against IC50 results in a wide distribution of 48h RoK for 
196 these compounds (Figure 3B). Interestingly a number of initially slow acting compounds now show a 
197 48h RoK within the TCP1 target range (>chloroquine) and presumably reflect a shorter lag phase in 
198 their action, such as the 24hr lag phase reported for pyrimethamine.10 The majority of compounds, 
199 however, still show a BRRoK PC1 more similar to atovaquone, and thus potentially a longer lag 
200 phase. To explore this, compounds with two predicted slow-acting MoA16,20,2226,29,30,34,3639 were 
201 correlated with BRRoK48h; 38 were DHODH inhibitors (Figure 4A, Table S7) and 18 were bc1 complex 
202 inhibitors (Figure 4B, Table S7). Unfortunately, due to small sample size, one-way ANOVA did not 
203 indicate statistical significance (p > 0.05) (Fig 4C) between these different MoA but did indicate that 
204 their longer lag phases resulted in higher BRRoK48h PC1 scores (Figure 4C). 
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206 Discussion 
207 The next-generation antimalarial drugs should rapidly eliminate parasite burden, ideally as 
208 fast as artesunate, but at least as fast as chloroquine.1 Whilst we have previously used the BRRoK6h 
209 assay to measure the relative RoK for 370 Malaria Box compounds, here we show that BRRoK6h data 
210 provides links to the antimalarial MoA (with PfATP4 > parasite hemoglobin catabolism > DHFR-TS > 
211 DHODH > bc1 complex) and that comparison with scaffold sub-structures identified five core 
212 scaffolds with the relative RoK: diamino-glycerols > 2-(aminomethyl)phenol > 2-phenylbenzimidazole 
213 > 8-hydroxyquinolines > triazolopyrimidine. We also predicted that compounds with minimal activity 
214 at 6h might have a lag phase, like atovaquone and DSM265.7,10,35 Thus, we determined the RoK of 
215 apparently slow-acting compounds using a BRRoK48h assay and show that many of the slow-acting 
216 compounds are likely DHODH and bc1 complex inhibitors.  In short, compounds in the Malaria Box 
217 with similar targets and chemical core substructure exhibit similar time-dependant RoK dynamics. 
218 Although our study is limited to a library of 400 compounds that lack a full biochemical target 
219 validation, it provides the proof-of-principle that BRRoK data offers an opportunity to rapidly 
220 prioritize compounds in the TCAMS, or other, library by informing predictions of structure-activity 
221 and MoA. Moreover, we note that using the BRRoK assay at two-time points, 6 and 48h, we not only 
222 have the potential to rapidly identify and discriminate between compounds that meet the ideal and 
223 minimum TCP1 criteria, but also identify compounds that likely exhibit a lag time in drug action 
224 between 6 and 48h. This BRRoK assay format, however, does not provide a reliable assessment of 
225 the extent and timing of this lag time, as would be reported by a recrudescence assay.10 
226 A compounds immediate cytocidal activity likely results from the nature of the target and 
227 the ease of access to the target. The first aspect considers how quickly a deficit in this targets 
228 function will lead to cell death  i.e. its MoA. In vitro assays of RoK report that antimalarial drugs 
229 with a similar MoA result in similar RoK.7,10 We have significantly extended this observation here for 
230 the open Source Malaria Box, a critical collection of antimalarial drug discovery compounds. Whilst 
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231 an important caveat is that for most compounds described the target association is tentative, this 
232 library is still the best described and investigated resource in this endevour.21 Nonetheless, here we 
233 were able to consider five MoA groups due to availability of  in vitro PRR data and at least 10 MMV 
234 compounds annotated for each MoA from a range of sources.16,20,21,27,28,35 Specifically; (i) PfATP4 
235 (Figure 1A): 33 compounds are annotated as PfATP4 inhibitors (Figure 1A).20,29 In vitro PRR data are 
236 available for exemplar PfATP4 inhibitors (+)-SJ733,3621 a dihydroisoquinoline with a slow-to-
237 moderate RoK, and KAE609/NITD609,27 a spiroindolone with a moderate to fast RoK. Most potential 
238 Malaria Box PfATP4 inhibitors were reported as having a BRRoK6h between the moderate mefloquine 
239 10 (comparable to the PRR reference pyrimethamine10) and the rapidly-acting dihydroartemisinin. 
240 The fastest-acting PfATP4 inhibitor was the spiroindolone MMV396749, with several studies 
241 reporting a fast to moderate cytocidal activity for PfATP4 inhibitors.7,16,20,21,27,29 The Malaria Box also 
242 contains five structural analogues of the slower acting PfATP4 inhibitor (+)-SJ733; two have PC1s 
243 falling between the fast-acting dihydroartemisinin and chloroquine with the remaining three 
244 between mefloquine and atovaquone, supporting the prediction of a moderate to slow RoK of the 
245 dihydroisoquinolines. (ii) Plasmodium dihydrofolate reductase-thymidylate synthase (DHFR-TS) 
246 (Figure 1B): 14 compounds are annotated as DHFR-TS inhibitors, clustering with known antifolate 
247 antimalarial drugs that target DHFR-TS, P218, pyrimethamine, and WR99210.29,4042 Pyrimethamine 
248 has a lag phase of 24 h, which is the slowest RoK after ATQ.10 The BRRoK6h confirms slow cytocidal 
249 activity for this cluster, between slow-acting atovaquone and moderate-acting pyronaridine. (iii) 
250 Dihydroorotate dehydrogenase (DHODH) (Figure 1C): 43 compounds are annotated as DHODH 
251 inhibitors, and BRRoK6h show that they share a slow initial cytocidal action. This slow RoK correlates 
252 with the atovaquone-like in vitro PRR data for DSM26535, due to its 24-48h lag phase. One outlier, 
253 MMV666102, falls between pyronaridine and mefloquine showing a slow-to-moderate cytocidal 
254 action. Whilst no additional target information is available, we predict that this compound may have 
255 additional targets. (iv) bc1 complex inhibitors: 18 compounds are annotated as bc1 complex 
256 inhibitors and are slowly cytocidal in the BRRoK6h and are comparable to atovaquone which shares 
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257 the same MoA.10 Comparing BRRoK with the predicted MoA for all four groups indicates that 
258 compounds with a similar MoA have similar RoK. The predicted MoA used here was primarily 
259 obtained through metabolomics16,29,30 and readily highlights the potential for BRRoK to complement 
260 such studies. (v) Parasite hemoglobin catabolism: Allman et al.,29 reports a compound group in the 
261 Malaria Box that perturbs parasite hemoglobin catabolism. Parasite hemoglobin catabolism 
262 compounds formed our second fastest-acting cluster (Figure 1E). However, as expected, the BRRoK6h 
263 data reveals a broad RoK range for these compounds, which agrees with metabolomics data, as 
264 these compounds have a range of predicted targets. For example, chloroquine, known for 
265 accumulation within the digestive vacuole of Plasmodium, clusters with this group, but the resulting 
266 metaprint is divergent, due to the overall lack of significant metabolic changes or dysregulation 
267 induced by chloroquine.29,43 MMV390048, which inhibits the phosphatidylinositol 4-kinase (PI4K), 
268 and AZ412, which inhibits the putative vacuolar ATPase,12,29,44 also clusters with this group. 
269 Interestingly, as expected from compounds with different targets, the BRRoK6h appears to form 
270 subclusters within this group. Upon additional target data availability, we would predict that this 
271 currently broad class of compounds could be further categorised into slow, moderate, and fast-
272 acting groups.
273 A second means to classify compounds for comparison to the BRRoK6hr data is through their 
274 chemical structure (Figure 2). Our analysis suggests that structurally similar compounds exert a 
275 similar RoK. This is not surprising if they share the same target, and our analysis suggests that 
276 medicinal chemistry may not only improve IC50 potency for candidates but may also help improve 
277 RoK within chemical class and a well-defined MoA. For example, all five triazolopyrimidine scaffold 
278 members (Figure 2A) inhibit DHODH and are structural analogs of DSM265, a known slow-acting 
279 compound in clinical trials.35 However, their PC1 varies between 23 and 67, highlighting room to 
280 influence the initial cytocidal action within the limits of this chemical class and the intrinsic limits of 
281 the MoA. A range of slow cytocidal activity is also reported for 8-hydroxyquinolines (PC1 of 8.8-95.4) 
282 (Figure 2B), with one annotated as a DHODH inhibitor. We also report two fast-acting scaffolds: 
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283 diamino-glycerols and 2-(aminomethyl)phenol (Figure 2C-D).  The diamino-glycerol is the fastest 
284 scaffold described here, which agrees with a predicted MoA as four of these nine compounds are 
285 PfATP4 inhibitors.16,20,29 It would be interesting to investigate whether the remaining five compounds 
286 also affect PfATP4. Three of these five compounds are designated as probe-like and were not 
287 characterised in metabolomic studies that focussed on drug-like compounds in the Malaria Box.29 
288 Furthermore, five compounds are structurally related to the amino alcohol-carbazoles, which has 
289 demonstrated long-lasting and fast-acting antimalarial activity in vivo,45 in agreement with BRRoK6h 
290 measurements here. The next most fast-acting compound cluster is the 2-(aminomethyl)phenol 
291 scaffold. Interestingly, BRRoK6h indicated five of 14 compounds in this scaffold are likely inhibitors of 
292 parasite hemoglobin catabolism (PC1 between -79 and -51),29 which is the second fastest-acting 
293 compound cluster according to MoA comparisons and agrees with our chemical clustering analyses. 
294 Eight compounds are probe-like, so metabolomic data are not available, however, Creek et al.43 have 
295 shown an artemisinin-like metabolomic signature for three of these compounds, thus confirming the 
296 relative fast action of this scaffold. These data illustrate how BRRoK data can be effectively 
297 employed alongside other datasets to inform how decisions are made regarding the selection of 
298 targets for further study and/or development.
299 Given the short timeframe of the BRRoK6h, a second attribute that may influence RoK is ease 
300 of target access. Within our in vitro assay, compounds must migrate through up to four membranes 
301 to access a target within an infected erythrocyte and the biophysical parameters of size, 
302 hydrophobicity, hydrogen-bonding capabilities and charge may contribute to how easily access 
303 occurs. Another consideration for compounds with a basic charge at physiological pH, is that of 
304 access/accumulation within the digestive vacuole in the trophozoite, irrespective of the final target 
305 site. Biophysical properties span charge type, lipophilicity, polarity, size, 3D-shape, flexibility and H-
306 bond properties.46 To investigate what influence molecular properties have on BRRoK6h, we 
307 calculated key biophysical properties for Malaria Box compounds (PC1) (Table S8) and compared 
308 compounds with relative RoK faster than DHA and slower than atovaquone to see if extremes of RoK 
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309 are associated with significantly different molecular properties. We expanded analyses to include 
310 compounds reported to have a common, fast MoA (PfATP4), a common, slow MoA (bc1 complex), a 
311 common fast core (2-(Methylamino)-Phenols, 2-MAP), and a common, slow core (2-
312 Phenylbenzimidazoles, 2-Ph-Bz) (Table S8-9). These analyses do not reveal molecular property 
313 differe ces associated with BRRoK, although an important limitation here are the numbers of 
314 compounds in each group. Finally, we compared individual compounds with the fastest BRRoK6h and 
315 slowest BRRoK6h in the five MoA clusters investigated here and found some small differences (Table 
316 S10). The fastest compound in each MoA often has a lower MW, less rotatable bonds and is more 
317 aromatic in nature compared to the slowest, suggesting that careful biophysical property control 
318 may allow compound design to achieve improvements in RoK within a well-defined MoA/chemical 
319 class.
320 Perhaps the key benefit of RoK analysis considering both the MoA and chemical substructure 
321 is that outliers emerge that would appear to warrant additional validation or follow up. An example 
322 from this study are the three 1,2-diaza-9-fluorenones (MMV666021, MMV6666026 and 
323 MMV665934) for which the proposed MoA is the bc1 complex, which would imply a very slow RoK. 
324 However, we instead found that two of these have very fast BRRoK. Also, of interest is the structural 
325 singleton MMV142383, which has the fastest RoK (PC1= -131.5) and is categorised as acting by 
326 hemoglobin catabolism. Exceptions found using sub-structure analysis may have either 
327 miscategorized MoA or alternatively, they may have more than one MoA. The latter would be of 
328 particular interest as would theoretically lead to less resistance if more than one target is involved. 
329 In summary, we provide a demonstration that for leading antimalarial drug discovery 
330 compounds that their RoK are related to their MoA, and that a compounds RoK is also likely 
331 modified by factors that affect target access. Thus, as we use medicinal chemistry to improve 
332 compound potency, we could also influence the RoK for some scaffolds. Our modified BRRoK assay 
333 provides the necessary throughput for drug discovery and a critical decision-making tool to support 
334 development campaigns. Although our study was performed on a small pool of compounds, the 
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335 scaffolds we identified provide a strong basis for discovery antimalarial prioritization. Our core 
336 analysis approach has identified two scaffolds, diamino-glycerols, and 2-(aminomethyl) phenol, that 
337 exhibit fast cytocidal action, inviting medicinal chemistry improvements towards possible TCP1 
338 candidates. Some less-represented scaffolds have also been identified with fast cytocidal action, and 
339 medici al chemistry may allow discovery of compounds that meet the TCP1 profile. Further insights 
340 might be gained from our data, as targets are defined for additional MMV compounds.
341
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479
480 Figure 1.  Correlating mode of drug action with the BRRoK6h in the MMV Malaria Box compounds. 
481 Zero-meaned PC1 data for known antimalarial drugs (open squares), all Malaria Box compounds 
482 (grey filled squares) and Malaria Box compounds predicted to use the indicated MoA (black filled 
483 circles) for (A) PfATP4, (B) parasite hemoglobin catabolism, (C) dihydrofolate reductase-thymidylate 
484 synthase (DHFR-TS), (D), dihydroorotate dehydrogenase (DHODH) and (E) mitochrondrial bc1 
485 complex are plotted against their IC50. Faster initial rates of cytocidal activity are represented with 
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486 lower PC1 values. See Table S2 for PC1, IC50 and predicted MoA data for individual compounds.  (F) 
487 One-way ANOVA with post-hoc Tukey test comparing the BRRoK6h data7 for each MoA group 
488 (whisker plots represent the mean and SD)16,20,29,30.  = PfATP4 cluster, significantly different from all 
489 clusters (p < 0.01). ¥ = parasite hemoglobin catabolism (H catabolism), significantly different than 
490 DHODH and bc1 complex (p < 0.01). $ = DHFR-TS, significantly different than the bc1 complex (p < 
491 0.01). ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, 
492 piperaquine; PYN, pyronaridine; QN, quinine. 
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494
495
496 Figure 2. BRRoK6h data illustrates related compounds in the MMV Malaria Box that share a similar 
497 relative RoK. Zero-meaned PC1 data for known antimalarial drugs (open squares), all Malaria Box 
498 compounds (grey filled squares) and Malaria Box compounds sharing the indicated related core 
499 scaffolds (black filled circles) of (A) diamino-glycerols, (B) 2-(aminomethyl)phenol, (C) 2-
500 phenylbenzimidazole, (D) 8-hydroxyquinolines, and (E) triazolopyrimidine are plotted against their 
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501 IC50. Faster initial rates of cytocidal activity are represented with lower PC1 values. See Table S3 for 
502 PC1, IC50 and structures for individual compounds. (F) One-way ANOVA with post-hoc Tukey test 
503 comparing the BRRoK6h data7 for each group (whisker plots represent the mean and SD) based on 
504 the indicted related core scaffold.  = Diamino-glycerols, significantly different than 2-
505 phenylbenzimidazole, 8-hydroxyquinolines, and triazolopyrimidine scaffolds (p < 0.01). $ = 2-
506 (aminomethyl)phenol, significantly different than 2-phenylbenzimidazole, 8-hydroxyquinolines, and 
507 triazolopyrimidine scaffolds (p < 0.01). ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; 
508 MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine; QN, quinine. 
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510
511
512 Figure 3. Distribution of BRRoK (PC1) against IC50 for the MMV Malaria Box compounds.
513 Zero-meaned PC1 data for 178 compounds in the MMV Malaria Box (grey filled squares) and 7 
514 benchmark antimalarial drugs (open squares) are plotted against their IC50 for (A) 6hr and (B) 48h. 
515 See Table S2 for PC1 and IC50 data for individual compounds. ATQ, atovaquone; CQ, chloroquine; 
516 DHA, dihydroartemisinin; MQ, mefloquine; PPQ, piperaquine; PYN, pyronaridine; QN, quinine.
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518
519
520 Figure 4. Correlating mode of drug action with the BRRoK48h in the MMV Malaria Box compounds. 
521 Zero-meaned PC1 data for known antimalarial drugs (open squares), all Malaria Box compounds 
522 (grey filled squares) and Malaria Box compounds with a predicted MoA (black filled circles) that 
523 targets, (A) DHODH or (B) the bc1 complex are plotted against their IC50. See Table S2 for PC1, 
524 IC50 and predicted MoA data for individual compounds.  (C) One-way ANOVA with post-hoc Tukey 
525 test comparing the BRRoK48h data (whisker plots represent the mean and SD) for both groups 
526 clustered based on the indicted predicted MoA data16,20,29,30. No significant difference was found (p = 
527 0.6).  ATQ, atovaquone; CQ, chloroquine; DHA, dihydroartemisinin; MQ, mefloquine; PPQ, 
528 piperaquine; PYN, pyronaridine; QN, quinine.
529
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Table S1: The antimalarial drugs were sourced from SigmaAldrich and prepared as shown below and were stored 
at ?!9@A#4 The Malaria Box was provided by MMV (www.mmv.org) and was provided as 20CD% solutions of 10CmM 
concentration in DMSO and stored at ?!9@A#4 
Drug/compound Stock Concentration Solvent
Atovaquone (AQ) 10mM DMSO
Artemether 50mM Ethanol
Chloroquine 100mM Deionized water
Dihydroartemisinin 50CmM Methanol
Mefloquine 50CmM DMSO
Piperaquine 100mM Ethanol
Pyronaridine 100mM Deionized water
Quinine 50mM Ethanol
Malaria Box compounds 10mM DMSO
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Figure S1: Equipotent IC50 concentration-dependent loss of bioluminescence for standard antimalarial drugs. The 
mean (error bars represent ±SD from three biological replicates) bioluminescence signal, normalized against an 
untreated control, remaining after a 6 (closed circles) or 48Ch (open squares) exposure to the indicated fold-IC50 
concentration of drug. A serial 3-fold dilution from H@I@#50 to 94**@I@#50 is reported. See Figure S1 and S2 for 178 
compounds of the MMV Malaria Box compounds. 
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Table S4 is to be used in conjunction with panels (drug-like) D1 to D11 and (probe-like) P1 to P10 in Figures S2 and 
S3, respectively. Listed below are the Compound ID for the MMV Malaria Box compounds tested in this study. The 
panel on which the dose-response curve for that compound is shown in these supplementary materials is indicated 
below.
COMPOUND_ID Drug-Like Position COMPOUND_ID Probe-Like Position 
MMV019066 D1 MMV396680 P1
MMV011259 D1 MMV666601 P1
MMV006278 D1 MMV008294 P1
MMV006427 D1 MMV666688 P1
MMV020439 D1 MMV666062 P1
MMV396672 D1 MMV020885 P1
MMV019871 D1 MMV008416 P1
MMV665874 D1 MMV665977 P1
MMV001246 D1 MMV666607 P1
MMV665916 D2 MMV007695 P2
MMV011099 D2 MMV666101 P2
MMV020492 D2 MMV666596 P2
MMV665782 D2 MMV396679 P2
MMV665876 D2 MMV666691 P2
MMV396703 D2 MMV000642 P2
MMV006937 D2 MMV666600 P2
MMV665820 D2 MMV006309 P2
MMV007116 D2 MMV666023 P2
MMV020548 D3 MMV007160 P3
MMV019258 D3 MMV085203 P3
MMV011256 D3 MMV007384 P3
MMV666693 D3 MMV665827 P3
MMV008956 D3 MMV396678 P3
MMV007839 D3 MMV006861 P3
MMV000662 D3 MMV006457 P3
MMV666103 D3 MMV396693 P3
MMV666057 D3 MMV665908 P3
MMV007564 D4 MMV666054 P4
MMV000563 D4 MMV007127 P4
MMV665850 D4 MMV006389 P4
MMV666105 D4 MMV665934 P4
MMV666072 D4 MMV665994 P4
MMV665909 D4 MMV665980 P4
MMV665940 D4 MMV007577 P4
MMV665899 D4 MMV000720 P4
MMV665961 D4 MMV006753 P4
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MMV666108 D5 MMV666125 P5
MMV006188 D5 MMV007574 P5
MMV665799 D5 MMV007557 P5
MMV008149 D5 MMV000699 P5
MMV019074 D5 MMV009127 P5
MMV665798 D5 MMV006250 P5
MMV666067 D5 MMV007199 P5
MMV665939 D5 MMV085471 P5
MMV009060 D5 MMV665797 P5
MMV019758 D6 MMV666095 P6
MMV665901 D6 MMV019690 P6
MMV666081 D6 MMV019241 P6
MMV666009 D6 MMV665783 P6
MMV019746 D6 MMV000787 P6
MMV666093 D6 MMV666106 P6
MMV007571 D6 MMV666022 P6
MMV665954 D6 MMV498479 P6
MMV666075 D6 MMV007396 P6
MMV666070 D7 MMV665923 P7
MMV000788 D7 MMV007228 P7
MMV665879 D7 MMV073843 P7
MMV006913 D7 MMV667492 P7
MMV008127 D7 MMV007764 P7
MMV403679 D7 MMV665886 P7
MMV019700 D7 MMV396664 P7
MMV019670 D7 MMV086103 P7
MMV001344 D7 MMV084434 P7
MMV019124 D8 MMV666692 P8
MMV006767 D8 MMV665836 P8
MMV007808 D8 MMV665875 P8
MMV396681 D8 MMV396726 P8
MMV019202 D8 MMV006962 P8
MMV075490 D8 MMV396652 P8
MMV007374 D8 MMV008160 P8
MMV020700 D8 MMV665810 P8
MMV007906 D8 MMV665927 P8
MMV000911 D9 MMV009085 P10
MMV007430 D9 MMV638723 P10
MMV007977 D9 MMV396594 P10
MMV665883 D9 MMV396665 P10
MMV084940 D9 MMV396723 P10
MMV000963 D9 MMV011832 P10
MMV006319 D9 MMV665898 P10
MMV000972 D9 MMV665814 P10
MMV665904 D9 MMV007041 P10
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MMV006820 D10 MMV645672 P11
MMV011576 D10 MMV011438 P11
MMV020651 D10 MMV665840 P11
MMV396705 D10 MMV667489 P11
MMV007881 D10 MMV396770 P11
MMV008212 D10
MMV007791 D10
MMV665843 D10
MMV396595 D10
MMV019762 D11
MMV020942 D11
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Figure S2. Equipotent-IC50 concentration-dependent loss of bioluminescence plots for drug-like compounds 
screened from the MMV Malaria Box. The data for these drug-like compounds are shown on seven panels (D1-11). 
The mean (error bars represent SD from three biological replicates) bioluminescence signal, normalised against an 
untreated control, remaining after a 6 h (closed circles) or 48 h (open squares) exposure to the indicated fold-IC50 
concentration of drug.
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Figure S3. Equipotent-IC50 concentration-dependent loss of bioluminescence plots for probe-like compounds 
screened from the MMV Malaria Box. The data for these probe-like compounds are shown on 10 panels (P1-10). 
The mean (error bars represent SD from three biological replicates) bioluminescence signal, normalised against an 
untreated control, remaining after a 6 h (closed circles) or 48 h (open squares) exposure to the indicated fold-IC50 
concentration of drug.
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Details of Principle Components Analysis of 9xIC50 to 0.33xIC50 endpoints for 178 Malaria Box compounds
Principle components analysis was performed on the 0.3x, 1x, 3x and 9x endpoints for BRRoK assessed at the 48 h 
timepoint using the KNIME analytics platform (https://www.knime.org/) to reduce the dimensionality of these 
data set, allowing the concentration-rate relationship to be captured in one parameter. This analysis reports that 
two principle components (PC1 and PC2) explain 92% of the variance in the parameters, with the first principle 
component explaining 78% of the total variance in the four original variables. A zero-meaned PC1 value was used 
to represent the BRRoK48hr parameter.
Table S5. Eigenvalues and breakdown of % variance and cumulative variance explained by each principle 
component. 
Eigenvalue % Variance explained Cumulative variance explained
PC 1 1820.361 78 78
PC 2 319.7312 14 92
PC 3 130.3651 6 97
PC 4 68.0949 3 100
Table S6. Eigenvectors for each principle component showing the contribution (non-zero-meaned) that each 48 h 
BRRoK readout at different equipotent concentrations makes to the principle components.
BRRok Readout PC1 PC2 PC3 PC4
9xIC50 0.27 0.64 0.66 0.29
3xIC50 -0.50 -0.50 0.45 0.55
1xIC50 -0.51 0.09 0.44 -0.73
0.33xIC50 -0.65 0.57 -0.42 0.27
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Table S9. The range of all the biophysical properties seen in each set are summarized. Also, see table S7 for 
individual compounds data. 
MW, molecular weight; LogP, log distribution coefficient; PSA, polar surface area (Å2); RB, rotatable bonds; HBD/HBA, hydrogen bond 
donor/acceptor; Fsp3; fraction of sp3 carbons; 2-MAP, 2-(Methylamino)-Phenols;  2-Ph-Bz, 2-PhenylBenzimidazoles
All compounds tested in 
MMV-Box (370)
Fast
MoA
Slow
MoA
Fast
Core
Slow
Core
Property PC1 <DHA PC1>ATQ PfATP4 bc1 2-MAP 2-Ph-Bz
LogD 1 to 5.5 2 to 6.5 1 to 5 1-8 2-4 3-7
MW 250-400 250-500 300-450 200-600 250-400 350-500
PSA <80 <90 =<90 =<80 =<60 =<90
RB =<9 =<9 =<8 =<7 =<7 =<6
HBD =<2 =<2 =<2 =<1 =<2 >=2
HBA =<6 =<6 =<5 =<5 =<4 =<4
Fsp3 0.0  0.6 0.0 - 0.5 <0.45 <0.4 <0.65 <0.2
No. Rings =<6 =<6 =<5 <5 <4 >=4
Basic pKa <10 <10 <10 <5 <11 <7
Acidic pKa >8 >6 >9 >9 >8 >10
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Table S10: Biophysical properties for compounds in the indicated modes of action. Also, see table S7 for individual 
compound data. 
MW, molecular weight; LogP, log partition coefficient; PSA, polar surface area (Å2); RB, rotatable bonds; HBD/HBA, hydrogen bond 
donor/acceptor; Fsp3; fraction of sp3 carbons
PfATP4 Hgb catabolism DHFR-TS DHODH bc1
Fastest 
RoK
Slowest 
RoK
Faste
st 
RoK
Slowest 
RoK
Fastest 
RoK
Slowest 
RoK
Fastest 
RoK
Slowest 
RoK
Fastest 
RoK
Slowest 
RoK
MMV 
396749
MMV 
000642
MMV 
1423
83
MMV 
011576
MMV 
006706
MMV 
667486
MMV 
666102
MMV 
006937
MMV 
665940
MMV 
084434
MW 368.4 469 310.4 445 359.5 261 252.3 279.3 293.3 358.4
LogP 4.18 5.51 5.43 2.6 3.93 1.3 2.56 4.31 3.4 3.5
PSA 68 59 42 83 48 89 58 50 48 60
RB 1 6 3 6 2 3 2 1 4 4
HBD 2 1 1 6 0 2 2 1 0 1
HBA 4 3 2 1 4 3 3 3 3 5
Fsp31 0.1 0.28 0.22 0.35 0.45 0.38 0.13 0.29 0.1 0.1
No. Rings 6 4 3 5 5 2 3 4 3 3
Basic pKa <5 - - - 8.8 8.4 6.8 <5 - -
Acidic pKa - - - - - - - - - -
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Additional Supplementary data
These Supplementary data files do not form part of the PDF but are available from the JAC 
Editorial Office (jac@bsac.org.uk) on request:
1. Table S2.xlsx
2. Table S3.xlsx
3. Table S7.xlsx
4. Table S8.xlsx
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